Skip to content

US · PEN · MEDICAL - DEVICES

Penumbra, Inc. (PEN) intrinsic value and stock valuation

$319.12as of 2026-11-21 · Mkt cap 12.73B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Penumbra, Inc. DCF and intrinsic value

InvestorsCraft values PEN with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from PEN’s statements →

Penumbra, Inc. Graham Number

Graham Number: $61.39d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Alameda, CA 94502 penumbrainc.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$1.4B+20.2% 5y CAGRd
20122025
Net income
$177.7M
20122025
Free cash flow
$174.9M
20132025
Total equity
$1.43B+17.5% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$1.4B$1.19B$1.06B$847.1M$747.6M
Operating income$189.3M$86.2M$73.6M$6.08M-$-7.5M
Net income$177.7M$14M$91M-$-2M$5.28M
EPSd$4.52M$356.8K$2.32M-$-52.85K$139.4K
Operating cash flow$238.7M$168.5M$97.3M-$-55.66M$9.5M
Capital expenditure-$-63.73M-$-21.18M-$-15.21M-$-19.3M-$-21.18M
Free cash flow$174.9M$147.3M$82.1M-$-74.96M-$-11.68M
Total assets$1.83B$1.53B$1.56B$1.37B$1.24B
Total debt$219.7M$223.4M$234.3M$235.8M$173.6M
Net debt$32.8M-$-101.02M$66.9M$165.9M$114.2M
Total equity$1.43B$1.15B$1.18B$998.9M$953.9M
Cash and short-term investments$544.8M$340.1M$289.2M$188M$254.9M
Income statement
20252024202320222021
Revenue$1.4B$1.19B$1.06B$847.1M$747.6M
Cost of revenue$461.2M$439.6M$375.9M$311.9M$272.2M
Gross profit$942.4M$755M$682.6M$535.2M$475.4M
Research and development expenses$89.8M$94.8M$84.4M$79.4M$104.6M
Selling, general and administrative expenses$663.4M$574M$506.5M$449.7M$378.3M
Other expenses$0.00$0.00$18.2M$0.00$0.00
Operating expenses$753.2M$668.8M$609.1M$529.1M$482.9M
Cost and expenses$1.21B$1.11B$985M$841.1M$755.1M
Interest income$16.3M$13.7M$6.83M$1.89M$2.87M
Interest expense$1.31M$1.42M$1.74M$1.75M$1.93M
Depreciation and amortization$17.5M$23.7M$27.3M$24.3M$16.4M
Ebitda$223.9M$46M$108.7M$30M$7.84M
Operating income$189.3M$86.2M$73.6M$6.08M-$-7.5M
Total other income/expenses, net$15.9M-$-65.36M$6.1M-$-2.19M-$-3M
Income before tax$205.1M$20.9M$79.7M$3.89M-$-10.5M
Income tax expense$27.4M$6.86M-$-11.3M$5.89M-$-13.12M
Net income$177.7M$14M$91M-$-2M$5.28M
Weighted average shares outstanding$38.9M$38.6M$38.4M$37.8M$36.8M
Weighted average diluted shares outstanding$39.3M$39.3M$39.2M$37.8M$37.9M
Balance sheet
20252024202320222021
Cash and short-term investments$544.8M$340.1M$289.2M$188M$254.9M
Net receivables$190M$167.7M$201.8M$203.4M$133.9M
Inventory$431.6M$406.7M$388M$334M$263.5M
Total current assets$1.22B$951.1M$915.4M$755.7M$681.5M
Property, plant and equipment, net$316.4M$267.8M$280.5M$280.4M$227.1M
Goodwill and intangible assets$173.6M$173M$249.4M$257.8M$257M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$609.8M$582.1M$640.9M$615.2M$562.8M
Total assets$1.83B$1.53B$1.56B$1.37B$1.24B
Accounts payable$34.7M$31.3M$27.2M$26.7M$13.4M
Short-term debt$16.2M$14.6M$13.4M$12M$9.98M
Deferred revenue$0.00$940K$6.99M$9.16M$0.00
Total current liabilities$183.1M$158.3M$151.1M$144.9M$123.2M
Long-term debt$203.5M$208.8M$220.9M$223.8M$163.6M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$215.8M$223.9M$226.2M$227.1M$167.1M
Capital lease obligations$219.7M$223.4M$234.3M$235.8M$173.6M
Total liabilities$398.9M$382.3M$377.4M$372M$290.3M
Common stock$40K$40K$40K$40K$40K
Retained earnings$237.7M$60M$134.9M$43.9M$45.9M
Accumulated other comprehensive income (loss)$4.35M-$-5.84M-$-3.15M-$-8.12M-$-2.63M
Total equity$1.43B$1.15B$1.18B$998.9M$953.9M
Total investments$357.9M$15.7M$121.7M$118.2M$195.5M
Total debt$219.7M$223.4M$234.3M$235.8M$173.6M
Net debt$32.8M-$-101.02M$66.9M$165.9M$114.2M
Cash flow statement
20252024202320222021
Net income$177.7M$14M$91M-$-2M$5.28M
Depreciation and amortization$17.5M$23.7M$30.6M$27.6M$19.5M
Stock-based compensation$59.2M$46.2M$0.00$0.00$0.00
Change in working capital-$-42.72M-$-23.78M-$-79.08M-$-121.53M-$-66.71M
Accounts receivable-$-19.51M$26.6M-$-270K-$-69.86M-$-21.34M
Inventory-$-26.48M-$-65.66M-$-67.71M-$-74.63M-$-51.55M
Accounts payable$3.07M$4.17M$1.1M$13.4M-$-1.56M
Net cash provided by operating activities$238.7M$168.5M$97.3M-$-55.66M$9.5M
Investments in property, plant and equipment-$-63.73M-$-21.18M-$-15.21M-$-19.3M-$-21.18M
Acquisitions, net$0.00$0.00-$-990K$0.00$2.92M
Net cash used for investing activities-$-404.59M$77.6M-$-16.08M$54.8M-$-21.73M
Common stock issued$31.8M$17.2M$20.4M$21.6M$18.4M
Common stock repurchased$0.00-$-100.39M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$26.5M-$-87.01M$16.2M$11.6M$840K
Net change in cash-$-137.51M$156.9M$97.6M$10.5M-$-10.29M
Cash at end of period$186.9M$324.4M$167.5M$69.9M$59.4M
Operating cash flow$238.7M$168.5M$97.3M-$-55.66M$9.5M
Capital expenditure-$-63.73M-$-21.18M-$-15.21M-$-19.3M-$-21.18M
Free cash flow$174.9M$147.3M$82.1M-$-74.96M-$-11.68M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Penumbra, Inc.

        Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

        CEO
        Adam Elsesser
        Employees
        4.7K
        Beta
        0.70

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Penumbra, Inc. (PEN)?

        Penumbra, Inc. (PEN) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PEN undervalued?

        PEN trades at a price of $319.12 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.